Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Appili Therapeutics Inc. (T:APLI)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: #21-1344 Summer Street
Tel: N/A
IR: See website
Key People
Ian C. Mortimer
Independent Chairman of the Board
Armand Balboni
Chief Executive Officer, Director
Kimberly Stephens
Chief Financial Officer, Corporate Secretary
Myriam Triest
Senior Director - Product Development
Don Cilla
Chief Development Officer
Yoav Golan
Chief Medical Officer
Business Overview
Appili Therapeutics Inc is a Canada-based pharmaceutical company. The Company is focused on the acquisition and development of treatments targeting infectious disease. The Company is focused on building and advancing adverse portfolio of anti-infective programs. The Company's anti-infective portfolio includes ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir. The ATI-2307 is a clinical-stage antifungal candidate in development for severe and difficult-to-treat invasive fungal infections. The ATI-1701 is a vaccine candidate for tularemia. The ATI-1503 is a drug discovery program aimed at generating a class of antibiotics with broad spectrum activity against gram-negative superbugs. The ATI-1501 employs its taste-masked, oral-suspension technology with metronidazole for the patients with difficulty swallowing.
Financial Overview
For the six months ended 30 September 2020, AppiliTherapeutics Inc revenues was not reported. Net lossincreased 72% to C$5.1M. Higher net loss reflects Researchand development - Remaining increase from C$609K to C$2.1M(expense), General and administrative - Balancing increaseof 38% to C$1.4M (expense), Stock-based compensation in G&Aexpenses increase from C$176K to C$510K (expense).
Employees: 11 as of Mar 31, 2019
Reporting Currency: Canadian Dollars
Enterprise value: $61.18M as of Sep 30, 2020
Annual revenue (TTM): $0.20M as of Sep 30, 2020
EBITDA (TTM): -$8.21M as of Sep 30, 2020
Net annual income (TTM): -$7.54M as of Sep 30, 2020
Free cash flow (TTM): -$5.94M as of Sep 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 62,575,368 as of Jan 11, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization